Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the FDA's clearance of its Investigational New Drug application for KT-413, a targeted protein degrader aimed at treating relapsed/refractory B cell lymphomas. This represents the company's third IND clearance in 2021 and advances their clinical pipeline. KT-413 targets MYD88-mutant diffuse large B-cell lymphoma by degrading IRAK4 and IMiD substrates to enhance anti-tumor activity. Kymera aims to revolutionize treatment through its innovative Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) will host a virtual R&D Day for analysts and investors on December 16, 2021, from 8:30 a.m. to 11:00 a.m. ET. This event will feature presentations from key leadership, including CEO Nello Mainolfi and Chief Medical Officer Jared Gollob. Attendees will receive updates on Kymera’s lead programs, including KT-474 Phase 1 trial data, IRAKIMiD (KT-413), STAT3 (KT-333), and new clinical pathways. The company aims to advance targeted protein degradation therapies to treat significant diseases.
Kymera Therapeutics (NASDAQ: KYMR) presented significant preclinical data on its STAT3 degrader program at the SITC Annual Meeting. The study demonstrated that KTX-201, a tool STAT3 degrader, effectively inhibited tumor growth in models of solid and hematologic malignancies. Notably, KTX-201 enhanced the efficacy of anti-PD1 therapy, showing promising potential to remodel the tumor microenvironment and sustain immunological memory. The company plans to advance KT-333, a first-in-class STAT3 degrader, into Phase 1 clinical trials by the end of 2021, targeting both solid tumors and hematological malignancies.
Kymera Therapeutics (NASDAQ: KYMR) reported significant progress in its clinical trials for novel protein degrader drugs. In a Phase 1 trial, KT-474, an IRAK4 degrader, achieved up to 96% degradation in blood and 97% inhibition of pro-inflammatory cytokines. The FDA cleared its IND application for KT-333, its STAT3 degrader, expected to enter clinical trials by year-end 2021. The company will host a virtual R&D Day on December 16, announcing further data and plans for its drug pipeline.
Kymera Therapeutics (NASDAQ: KYMR) announced the presentation of preclinical data on its STAT3 degrader program at the upcoming Society for Immunotherapy of Cancer (SITC) and American Society of Hematology (ASH) Annual Meetings. The data focuses on the treatment potential for hematological malignancies and solid tumors. The lead candidate, KT-333, is nearing a Phase 1 trial. The findings suggest synergistic effects when combining STAT3 degraders with immune checkpoint inhibitors, promising advancements in treating previously undruggable cancers.
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced its participation in several upcoming virtual investor conferences. Notable events include a panel discussion at the UBS conference on November 1, 2021, and fireside chats at the Credit Suisse and Stifel healthcare conferences on November 11 and 15, respectively. Kymera focuses on targeted protein degradation, with its Pegasus™ platform addressing high-impact targets for immune-inflammatory diseases and cancers. For more details, webcasts will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) announced promising results from its Phase 1 trial of KT-474, a selective IRAK4 degrader. The Single Ascending Dose (SAD) trial showed up to 96% mean reduction of IRAK4 in PBMC within 48 hours, and up to 97% inhibition of pro-inflammatory cytokines. KT-474 was well-tolerated across all dose levels, with no serious adverse events reported. The MAD portion is underway, evaluating daily dosing. Kymera plans to present additional data before year-end, advancing its aim to target immune-inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced a conference call and webcast on October 27 to review data from the Single Ascending Dose (SAD) phase of the KT-474 trial. This presentation will feature Dr. Jared Gollob, the Chief Medical Officer, and will begin at 8:30 a.m. ET, followed by the conference call at 10:30 a.m. ET. The event aims to discuss Kymera's advancements in targeted protein degradation therapies, particularly for immune-inflammatory diseases and malignancies, highlighting its innovative Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) announced multiple presentations at the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Keynote presentations will detail safety, pharmacokinetics (PK), and pharmacodynamics (PD) data from the Single Ascending Dose (SAD) phase of the KT-474 Phase 1 trial in healthy volunteers. KT-474, an orally available IRAK4 degrader, targets immune-inflammatory diseases like rheumatoid arthritis. The company plans to present further data from the Multiple Ascending Dose (MAD) phase by year-end.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The first is the Morgan Stanley 19th Annual Global Healthcare Conference, featuring a live webcast on September 9, 2021, at 1:15 p.m. ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, with an on-demand presentation available from September 13, 2021, at 7:00 a.m. ET. Webcasts can be accessed on the Company's website, where archived versions will be available for 30 days.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
